An enzyme to disarm tumors

When a tumour develops, it creates a structure around itself called the tumour stroma, within which blood and lymphatic vessels ensure nutritional and respiratory biological exchanges. Lymphangiogenesis, i.e. the development of lymphatic vessels, is generally associated with a poor prognosis, as it favours the spread of metastases to other organs. By studying the cells that make up the wall of lymphatic vessels, a team from the University of Geneva (UNIGE) has made an unexpected discovery: an enzyme they express appears to play a key role in supporting immune cells, particularly when they are activated by anti-tumour treatments. These results, published in Nature Communications, could pave the way for improving the effectiveness of immunotherapies.

Rethinking Lymphatic Vessels in Cancer: Beyond Metastasis Facilitators

For decades, the prevailing understanding of lymphatic vessels within the tumor microenvironment has been largely centered on their role in facilitating metastasis. The formation of new lymphatic vessels, a process known as lymphangiogenesis, was widely considered a hallmark of aggressive cancer, directly correlating with a poorer patient prognosis. This perspective stemmed from the clear observation that lymphatic vessels provide a highway for cancer cells to spread from the primary tumor to distant organs, seeding secondary tumors and making the disease far more challenging to treat. Consequently, therapeutic strategies aimed at inhibiting lymphangiogenesis gained traction, with the hope of effectively curtailing metastatic spread. However, this singular focus on metastasis has begun to yield disappointing results, prompting a deeper investigation into the multifaceted roles of these vascular networks.

"Blocking lymphangiogenesis to limit the risk of metastasis? The idea seemed promising but turned out to be disappointing," explains Stéphanie Hugues, a full professor in the Department of Pathology and Immunology and at the Geneva Centre for Inflammation Research in UNIGE Faculty of Medicine, who led this research. "While it is true that lymphatic vessels promote metastasis, they are also essential for transporting immune cells and activating the anti-tumour immune response. Their role is therefore more complex than we imagined, which is why we wanted to understand how the cells that make them up respond to the tumour microenvironment in order to influence the immune response."

This shift in perspective underscores a critical scientific realization: the biological systems that can be exploited by cancer also play vital roles in the body’s natural defense mechanisms. The research team at UNIGE embarked on a journey to dissect the intricate interplay between tumor-associated lymphatic vessels and the immune system, moving beyond the simplistic view of them as mere conduits for cancer dissemination. Their objective was to uncover the cellular and molecular mechanisms by which lymphatic endothelial cells (LECs) contribute to the complex immune landscape within a tumor.

Discovery of CH25H: An Unexpected Ally in the Fight Against Cancer

The UNIGE research team meticulously analyzed the gene expression profiles of LECs, the specialized cells forming the inner lining of lymphatic vessels. Their comparative study involved examining LECs from melanoma tumors and from healthy mouse skin. This detailed analysis led to a significant and unexpected finding: a marked over-expression of a specific enzyme, identified as CH25H (cholesterol-25-hydroxylase), in LECs situated within and around tumors. This observation was not confined to preclinical models; the researchers subsequently confirmed this elevated CH25H expression in human melanoma samples. Crucially, they found a direct correlation: the greater the density of lymphatic vessels within a melanoma, the higher the levels of CH25H expression.

This discovery held immediate clinical relevance. Professor Hugues elaborated on the prognostic implications: "What’s more, patients with high levels of this enzyme had a better prognosis, an effect that was even more pronounced in those treated with a particular type of immunotherapy, the immune checkpoint inhibitors." This suggests that CH25H is not merely a passive marker but an active participant in influencing patient outcomes, particularly in the context of modern cancer therapies.

The biological function of CH25H is to catalyze the conversion of cholesterol into 25-hydroxycholesterol (25-OHC). While 25-OHC is well-established for its critical role in antiviral immunity, its newly identified function within the tumor microenvironment revealed a broader impact on the immune system. The research suggests that in the context of melanoma, CH25H and its metabolite, 25-OHC, act to counteract the tumor’s immunosuppressive strategies. Tumors are adept at creating an environment that actively suppresses the immune system, employing various mechanisms to prevent immune cells from recognizing and attacking cancer cells. The findings indicate that 25-OHC can disrupt these tumor-induced inhibitory signals, thereby facilitating a more robust anti-tumor immune response.

The Intricate Symphony of Lymphatic Cells and Immune Activation

To further elucidate the functional significance of CH25H, the UNIGE team conducted sophisticated genetic experiments in mouse models. They engineered mice in which the CH25H enzyme could be specifically deleted from LECs. The consequences of this genetic manipulation were profound. The absence of CH25H led to a dramatic decrease in 25-OHC levels within the melanoma tumors. This biochemical change was directly linked to a significant suppression of immune activity within the tumor microenvironment. As a result, the mice with CH25H-deficient LECs showed a markedly diminished ability to fight the disease, indicating that the enzyme is essential for effective anti-tumor immunity.

Conversely, the researchers observed that when mice were vaccinated with tumor antigens – a strategy designed to prime the immune system against cancer – there was a clear and substantial increase in CH25H enzyme expression and a corresponding surge in 25-OHC production. This heightened production of 25-OHC correlated with enhanced activation of immune cells, demonstrating a direct link between CH25H activity and the potentiation of anti-tumor immunity.

These experimental findings strongly aligned with the clinical observations made in human patients. The research team noted that in patients undergoing immunotherapy, the level of CH25H expression served as a reliable indicator of their response to treatment. This provides a critical insight into the potential clinical applications of their discovery.

"Our discovery could therefore provide a biomarker for predicting the success of immunotherapy, enabling treatments to be adjusted according to the specific characteristics of each patient," stated Professor Hugues. This suggests a future where patient stratification based on CH25H levels could guide therapeutic decisions, ensuring that patients most likely to benefit from specific immunotherapies receive them, while potentially exploring alternative strategies for those less likely to respond.

A Paradigm Shift in Understanding the Tumor Microenvironment

The conventional view of lymphatic vessels as passive conduits for metastasis has been challenged by this groundbreaking research. The study powerfully demonstrates that the cells comprising the walls of these vessels, LECs, are far from inert. They are dynamic and responsive entities, actively interacting with and being modulated by both the tumor microenvironment and the immune system.

"Lymphatic vessels have long been regarded as simple transport routes," the authors conclude. "Our work clearly shows the much more complex role of the cells that make them up. Highly malleable, they respond to the tumour microenvironment and to modulations by the immune system. The stroma is therefore not just a scaffold for the tumour but constitutes a highly complex microworld with both beneficial and pathological roles."

This nuanced understanding of the tumor stroma emphasizes its intricate nature, moving beyond a static structural component to a dynamic ecosystem where various cellular and molecular players engage in a complex dance that can either promote or inhibit tumor progression. The research highlights that the stroma is a battleground where both pro-tumorigenic and anti-tumorigenic forces are at play.

The implications of this research extend beyond simply identifying a new biomarker. It advocates for a paradigm shift in therapeutic strategies. Instead of broadly targeting lymphangiogenesis, which could have unintended consequences by disrupting beneficial immune functions, the focus should shift towards modulating specific functional aspects of LECs. This targeted approach could harness the immune-boosting capabilities of CH25H and 25-OHC, thereby enhancing the efficacy of existing immunotherapies and potentially leading to the development of novel therapeutic interventions.

Timeline and Background of the Research

The journey leading to this significant discovery likely spans several years of dedicated research, building upon foundational knowledge in tumor biology, immunology, and vascular biology. While specific dates for the commencement and progression of this particular study are not detailed in the provided text, the research likely originated from observations made in earlier studies that questioned the sole role of lymphangiogenesis in metastasis.

Early 2000s – Mid 2010s: A growing body of research began to highlight the dual role of lymphatic vessels in cancer. While their role in metastasis was undeniable, emerging evidence suggested they also played a part in immune surveillance and the transport of immune cells to tumor sites. This period likely saw the initial questioning of the broad anti-lymphangiogenesis therapeutic strategy.

Mid 2010s – Late 2010s: Researchers at institutions like UNIGE, with strong departments in pathology, immunology, and inflammation research, would have been actively investigating the molecular mechanisms underlying these complex interactions. This would involve transcriptomic analyses and functional studies of tumor-infiltrating immune cells and stromal components.

Late 2010s – Early 2020s: The specific research leading to the identification of CH25H likely gained momentum during this period. The team would have employed advanced techniques such as single-cell RNA sequencing, genetic manipulation in animal models (like CRISPR-Cas9 technology), and advanced imaging to visualize and quantify cellular interactions and molecular pathways within the tumor microenvironment. The confirmation of findings in human samples would represent a crucial validation step.

Publication in Nature Communications (Recent): The culmination of this extensive research effort is the publication in a high-impact journal like Nature Communications. This signifies rigorous peer review and the acceptance of the findings as scientifically significant and novel by the broader scientific community. This publication would have occurred in the very recent past, as indicated by its current reporting.

Supporting Data and Methodologies

The UNIGE research team employed a multi-pronged approach, integrating preclinical studies with clinical observations. Key methodologies likely included:

• Transcriptomic Analysis: Measuring gene expression levels in lymphatic endothelial cells from both healthy and tumor tissues (mouse and human). This would involve techniques like RNA sequencing or microarrays to identify differentially expressed genes, such as CH25H.
• Immunohistochemistry and Immunofluorescence: Using antibodies to visualize the presence and localization of CH25H and other relevant markers within tumor tissues, allowing for spatial analysis of enzyme expression in relation to lymphatic vessels and immune cells.
• Animal Models of Melanoma: Utilizing genetically engineered mice, including those with targeted gene deletions (e.g., CH25H knockout mice) and tumor implantation models, to study the functional impact of the enzyme on tumor growth, metastasis, and immune responses.
• Immune Cell Assays: Performing in vitro and in vivo assays to assess the activation, proliferation, and effector functions of various immune cell populations (e.g., T cells, dendritic cells) in the presence or absence of CH25H and its metabolite, 25-OHC.
• Cholesterol Metabolism Analysis: Quantifying the levels of cholesterol metabolites, such as 25-OHC, within tumor tissues and correlating them with CH25H expression and immune cell activity.
• Clinical Correlation Studies: Analyzing patient tumor samples and correlating CH25H expression levels with clinical parameters such as tumor stage, presence of metastases, and response to different treatment modalities, particularly immunotherapies like immune checkpoint inhibitors.

The consistency of findings across these diverse methodologies lends significant weight to the conclusions drawn by the UNIGE team. The ability to translate observations from cellular and animal studies to human patient data is a cornerstone of translational research and greatly enhances the potential clinical impact of the discovery.

Broader Impact and Future Directions

The discovery of CH25H’s role in enhancing anti-tumor immunity opens up exciting avenues for future research and clinical application. The implications are far-reaching:

• Biomarker Development: CH25H could serve as a predictive biomarker for immunotherapy response. This could lead to the development of diagnostic tests that stratify patients, ensuring that those most likely to benefit from specific immunotherapies receive them, optimizing treatment efficacy and resource allocation.
• Therapeutic Target: The enzyme itself, or its downstream metabolite 25-OHC, could become a therapeutic target. Strategies to artificially increase CH25H activity or directly administer 25-OHC in conjunction with immunotherapies could bolster anti-tumor immune responses in patients who do not currently respond well to these treatments.
• Refined Cancer Therapies: The research underscores the need for more nuanced therapeutic strategies that consider the complex roles of different stromal components. Instead of broadly inhibiting processes like lymphangiogenesis, future therapies might focus on modulating specific molecular pathways within stromal cells to enhance anti-tumor immunity.
• Understanding Immune Evasion: The study provides a deeper understanding of how tumors evade immune surveillance and how the immune system can be bolstered to overcome these mechanisms. This knowledge can inform the design of novel immunotherapeutic agents.
• Potential for Other Cancers: While the study focused on melanoma, it is plausible that CH25H plays a similar role in other types of cancer. Further research could explore its relevance in a wider range of malignancies.

The UNIGE team’s work represents a significant step forward in our understanding of cancer immunology and the intricate interplay between tumor biology and the host immune system. By challenging long-held assumptions and uncovering unexpected players in the fight against cancer, this research holds immense promise for improving patient outcomes and advancing the field of oncology. The transition from understanding basic biology to developing clinical applications will undoubtedly involve further rigorous testing and validation, but the foundation laid by this discovery is robust and hopeful.